ライフサイエンスコーパス: deep vein

1 dications ranging from serial imaging of the deep veins for 2 weeks to detect and treat only in case

2 mechanisms by which clots are formed in the deep veins have not been determined.

3 Thromboses limited to infrapopliteal leg deep veins (isolated distal deep vein thrombosis [IDDVT]

4 th postthrombotic, and 26 with nonthrombotic deep vein obstruction.

5 confirmed symptomatic VTE (two involving the deep veins, one peripheral vein and one pulmonary emboli

6 ent of thrombi structurally similar to human deep vein thrombi.

7 ancers and symptoms, vasomotor symptoms, and deep vein thromboses with tamoxifen.

8 There were no deep vein thromboses, with 1 superfificial venous thromb

9 The annual rates of deep vein thrombosis (1.46%; range, 1.15%-1.82%), pulmon

10 were possibly associated with TRF-budesonide-deep vein thrombosis (16 mg/day) and unexplained deterio

11 ermittent hemodialysis (2B); prophylaxis for deep vein thrombosis (1B); use of stress ulcer prophylax

12 evidence of heterogeneity between effects on deep vein thrombosis (266 versus 311, OR 0.85, 95% CI 0.

13 receiving TASQ versus 10% receiving placebo; deep vein thrombosis (4% v 0%) was more common in the TA

14 r and thromboembolic events (6/11), that is, deep vein thrombosis (4), transitory ischemic attacks (2

15 ffective than no IPC prophylaxis in reducing deep vein thrombosis (7.3% versus 16.7%; absolute risk r

16 cal practice adherence for the prevention of deep vein thrombosis (99% vs 85%, respectively; OR, 15.4

17 ved for interventions for pulmonary embolism/deep vein thrombosis (A 0%, B 24%, C 76%), inferior vena

18 y status of FHMI were highest for unprovoked deep vein thrombosis (adjusted hazard ratio, 1.69; 95% c

19 TEEs included deep vein thrombosis (DVT) alone in 49.7%, pulmonary emb

20 RATIONALE: Deep vein thrombosis (DVT) and its complication pulmonar

21 Deep vein thrombosis (DVT) and its complication, pulmona

22 Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE),

23 Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE),

24 Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE),

25 ratively may be at higher risk of developing deep vein thrombosis (DVT) and pulmonary embolism (PE).

26 Deep vein thrombosis (DVT) and pulmonary embolism are co

27 Monitoring for TEE and assessment of risk of deep vein thrombosis (DVT) by the Wells prediction rule

28 Accurate detection of recurrent same-site deep vein thrombosis (DVT) is a challenging clinical pro

29 Deep vein thrombosis (DVT) is a common but unpredictable

30 Deep vein thrombosis (DVT) is a common cardiovascular di

31 Deep vein thrombosis (DVT) is a major cause of cardiovas

32 ssessment of suspected ipsilateral recurrent deep vein thrombosis (DVT) is a major clinical challenge

33 The diagnosis of recurrent ipsilateral deep vein thrombosis (DVT) is challenging, because persi

34 Deep vein thrombosis (DVT) isolated to the calf veins (d

35 icoagulants in patients with cancer who have deep vein thrombosis (DVT) of the lower limbs.

36 months) and objectively documented proximal deep vein thrombosis (DVT) or pulmonary embolism, with a

37 Both IPC and GCS are recommended for deep vein thrombosis (DVT) prophylaxis in surgical patie

38 luation on the use of compression devices as deep vein thrombosis (DVT) prophylaxis methods in orthop

39 Enoxaparin sodium is widely used for deep vein thrombosis (DVT) prophylaxis, yet DVT rates re

40 Incidence rates for lower extremity deep vein thrombosis (DVT) range from 88 to 112 per 100

41 Deep vein thrombosis (DVT) with its major complication,

42 ght lower the risk of pulmonary embolism and deep vein thrombosis (DVT), although a cause-effect rela

43 Deep vein thrombosis (DVT), caused by alterations in ven

44 In patients with suspected lower extremity deep vein thrombosis (DVT), compression ultrasound (CUS)

45 actor, or a first unprovoked isolated distal deep vein thrombosis (DVT), generally should be treated

46 or a first unprovoked isolated distal (calf) deep vein thrombosis (DVT), has a low risk of recurrence

47 In patients with acute deep vein thrombosis (DVT), pharmacomechanical catheter-

48 The rates of deep vein thrombosis (DVT), pulmonary embolism (PE), and

49 normal clot properties can predict recurrent deep vein thrombosis (DVT), we studied 320 consecutive p

50 ority of them have proximal limb-threatening deep vein thrombosis (DVT).

51 rtality, all-cause mortality, and subsequent deep vein thrombosis (DVT).

52 resolution in humans after acute symptomatic deep vein thrombosis (DVT).

53 t-thrombotic syndrome (PTS) in patients with deep vein thrombosis (DVT).

54 in both formation and resolution of clots in deep vein thrombosis (DVT).

55 ceding week lowered the risk of proximal leg deep vein thrombosis (hazard ratio, 0.46; 95% CI, 0.27-0

56 r the risk for developing cannula-associated deep vein thrombosis (hazard ratio, 0.98; 95% CI, 0.98-1

57 also a predictor for developing proximal leg deep vein thrombosis (hazard ratio, 1.25; 95% CI, 1.06-1

58 P = 0.003]; mainly driven by a reduction in deep vein thrombosis (HR 0.523; 95% CI 0.349-0.783, P =

59 , 2.22; 95% confidence interval, 1.77-2.79), deep vein thrombosis (incidence rate ratio, 1.92; 95% co

60 Pediatric lower extremity deep vein thrombosis (LE-DVT) can lead to postthrombotic

61 (n = 5), nausea (n = 2), chest pain (n = 2), deep vein thrombosis (n = 1), transaminitis (n = 1), and

62 y adverse events (n = 7), cataracts (n = 4), deep vein thrombosis (n = 3), cerebral infarction (n = 2

63 3] vs 10% [67/690]; p=0.92) or recurrence of deep vein thrombosis (OR 0.93 [95% CI 0.66-1.31]; 6.4% [

64 Cs were associated with an increased risk of deep vein thrombosis (OR 2.55, 1.54-4.23, p<0.0001) but

65 ath (P = 0.007), disability (P = 0.012), and deep vein thrombosis (P = 0.048).

66 laxis compared with placebo reduced rates of deep vein thrombosis (pooled risk ratio, 0.51 [95% CI, 0

67 ophylaxis to IPC further reduced the risk of deep vein thrombosis (relative risk, 0.54; 95% CI, 0.32-

68 o significant difference in the incidence of deep vein thrombosis (relative risk, 1.76 [95% CI, 0.50-

69 28, 0.97]; p=0.04; I=0%) but not symptomatic deep vein thrombosis (risk ratio, 0.86 [95% CI, 0.59, 1.

70 CI, 0.74, 1.08]; p=0.26; I=0%), symptomatic deep vein thrombosis (risk ratio, 0.87 [95% CI, 0.60, 1.

71 , 0.58 [95% CI, 0.34, 0.97]; p=0.04) but not deep vein thrombosis (risk ratio, 0.90 [95% CI, 0.74, 1.

72 Rivaroxaban ranked first for prevention of deep vein thrombosis (RR 0.12 [95% CrI 0.06-0.22]).

73 Outcomes of interest were deep vein thrombosis (symptomatic and asymptomatic), pul

74 haracterization of pediatric upper extremity deep vein thrombosis (UE-DVT) and of UE postthrombotic s

75 frapopliteal leg deep veins (isolated distal deep vein thrombosis [IDDVT]) are frequently diagnosed i

76 Cannula-associated deep vein thrombosis after venovenous extracorporeal mem

77 ; secondary endpoints were the occurrence of deep vein thrombosis alone, pulmonary embolism alone.

78 The FN rate was 1.14% (8/701; 7 deep vein thrombosis and 1 PE) for pooled normal, very l

79 tional interpretations versus 1.5% (9/585, 5 deep vein thrombosis and 4 PE) in trinary interpretation

80 address this, we adopted a stenosis model of deep vein thrombosis and analyzed venous thrombi in pept

81 romboembolic deterrent stockings in reducing deep vein thrombosis and appeared to be as effective as

82 ontribute to pathologies, including arterial/deep vein thrombosis and atherosclerosis.

83 Effects of stasis-induced deep vein thrombosis and fibrinolysis on thrombosis were

84 mbolisms occurred, including six symptomatic deep vein thrombosis and four pulmonary emboli, resultin

85 ion, and inflammatory activity of T cells in deep vein thrombosis and its consequences for venous thr

86 tamoxifen and 16 with placebo, including one deep vein thrombosis and one stage I endometrial cancer

87 arin infusion is recommended for symptomatic deep vein thrombosis and portal and mesenteric vein thro

88 tect source thrombi and culprit emboli after deep vein thrombosis and pulmonary embolism (DVT-PE).

89 Deep Vein Thrombosis and pulmonary embolism (DVT/PE) is

90 In many patients with deep vein thrombosis and pulmonary embolism (venous thro

91 Deep vein thrombosis and pulmonary embolism are major he

92 or the initial 5 to 10 days of treatment for deep vein thrombosis and pulmonary embolism as well as f

93 or the initial 5 to 10 days of treatment for deep vein thrombosis and pulmonary embolism as well as f

94 Surgeon General's Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism in 2008 has

95 type of heparin thromboprophylaxis decreases deep vein thrombosis and pulmonary embolism in medical-s

96 mber 31, 2004, and in which risk factors for deep vein thrombosis and pulmonary embolism were assesse

97 ct on venous thromboembolism (which includes deep vein thrombosis and pulmonary embolism), but the ev

98 Deep vein thrombosis and pulmonary embolism, collectivel

99 omes and Measures: Rates of symptomatic VTE (deep vein thrombosis and pulmonary embolism, confirmed b

100 Venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism, is a common

101 y makes it the drug of choice for preventing deep vein thrombosis and pulmonary embolism.

102 ant agents are the mainstay of treatment for deep vein thrombosis and pulmonary embolism.

103 ovoked and unprovoked events, as well as for deep vein thrombosis and pulmonary embolism.

104 Cancer patients are at increased risk of deep vein thrombosis and pulmonary embolism.

105 e patient (7.7%) had both cannula-associated deep vein thrombosis and pulmonary embolism.

106 ent and included serious adverse events (eg, deep vein thrombosis and systemic complications) and min

107 diagnosis of proximal or inferior vena caval deep vein thrombosis and treated with CDT from 2005 to 2

108 n between FHMI and VTE applied to unprovoked deep vein thrombosis and was not explained by modifiable

109 Outcomes for graft and deep vein thrombosis are not favorable.

110 and symptoms plus imaging-confirmed proximal deep vein thrombosis but no chest imaging.

111 arket and are believed to reduce the risk of deep vein thrombosis by 40%.

112 Stasis of venous blood triggers deep vein thrombosis by activating coagulation, yet its

113 eduction in risk of the specific endpoint of deep vein thrombosis compared with no statin use (RR 0.7

114 8-year-old German-Caucasian man arrived with deep vein thrombosis DVT, pain, oedema and rubor of righ

115 ormatics Trial (GIFT) of Warfarin to Prevent Deep Vein Thrombosis enrolled 1650 patients aged 65 year

116 there were qualitative differences such that deep vein thrombosis exclusively afflicted the immunosup

117 The prevalence of deep vein thrombosis following decannulation from extrac

118 y were to: 1) analyze the cannula-associated deep vein thrombosis frequency after venovenous extracor

119 termine prevalence and predictors of femoral deep vein thrombosis in patients admitted to specialist

120 The prevalence of deep vein thrombosis in the cannulated vessel following

121 describe the prevalence of postdecannulation deep vein thrombosis in the cannulated vessel in adults

122 rategies are more effective in prevention of deep vein thrombosis in the elective total knee replacem

123 ormatics Trial (GIFT) of Warfarin to Prevent Deep Vein Thrombosis included patients aged 65 years or

124 However, the risk of subsequent deep vein thrombosis increased by 50% among VCF patients

125 ltrate the thrombus and vein wall rapidly on deep vein thrombosis induction and remain in the tissue

126 er randomized trial, 391 patients with acute deep vein thrombosis involving the iliac or common femor

127 Deep vein thrombosis is a major global health issue, res

128 e of symptomatic central venous line-related deep vein thrombosis is associated with worse outcomes,

129 treatment of acute proximal lower-extremity deep vein thrombosis is increasing in the United States

130 s a leading cause of maternal mortality, and deep vein thrombosis leads to maternal morbidity, with p

131 nnulation induced femoral cannula-associated deep vein thrombosis more frequently than femorojugular

132 nterventions; n=15 028) were included in the deep vein thrombosis network, 12 in the pulmonary emboli

133 Deep vein thrombosis occurred in 5 patients.

134 Obesity is a risk factor for deep vein thrombosis of the leg and pulmonary embolism.

135 s Seminar, we discuss pulmonary embolism and deep vein thrombosis of the legs.

136 Four participants with a scan showing no deep vein thrombosis on admission developed a deep vein

137 eep vein thrombosis on admission developed a deep vein thrombosis on repeat scanning over 21 days.

138 eported for 2 of 162 children (1.2%) who had deep vein thrombosis or central-line thrombosis as their

139 may arise from intravenous obstruction after deep vein thrombosis or from extrinsic venous compressio

140 us thromboembolism defined as a composite of deep vein thrombosis or non-fatal or fatal pulmonary emb

141 A FN study was defined as development of deep vein thrombosis or PE within 3 months after a negat

142 y, independent of the presence or absence of deep vein thrombosis or pulmonary embolism at the time o

143 with inflammatory bowel disease who develop deep vein thrombosis or pulmonary embolism often have ac

144 dy outcome was VTE (defined as patients with deep vein thrombosis or pulmonary embolism) that occurre

145 zation, or amputation for ischemia) and VTE (deep vein thrombosis or pulmonary embolism) were assesse

146 with newly diagnosed venous thromboembolism (deep vein thrombosis or pulmonary embolism) who were new

147 or cerebrovascular accident), venous events (deep vein thrombosis or pulmonary embolism), and respira

148 days after surgery or confirmed symptomatic deep vein thrombosis or pulmonary embolism).

149 onfirmed with compression ultrasound showing deep vein thrombosis or with chest CT showing pulmonary

150 95% confidence interval [CI], 0.77 to 0.91), deep vein thrombosis prophylaxis (OR, 0.88; 95% CI, 0.83

151 flow, improve compliance with antibiotic and deep vein thrombosis prophylaxis, and improve overall pe

152 management, neurology consultation, Holter, deep vein thrombosis prophylaxis, oral hypoglycemic inte

153 oley catheter removal, R = -0.089 [P = .63]; deep vein thrombosis prophylaxis, R = 0.101 [P = .59]).

154 Measure documentation, lipid management, and deep vein thrombosis prophylaxis.

155 With the baseline PICC-related deep vein thrombosis rate of 2.7% and pooled OR of 2.55,

156 oled RR, 4.30 95% CI, 1.60-11.54) and higher deep vein thrombosis rates (2.94 1.35-6.38).

157 analysis of 11 studies comparing the risk of deep vein thrombosis related to PICCs with that related

158 Deep vein thrombosis remains a major health problem nece

159 of post thrombotic syndrome in patients with deep vein thrombosis remains unknown.

160 Deep vein thrombosis screening was performed using a rig

161 PICCs are associated with a higher risk of deep vein thrombosis than are CVCs, especially in patien

162 cal trial of patients with acute iliofemoral deep vein thrombosis treated with a fixed-dose catheter

163 in the thrombotic vein, we identify a set of deep vein thrombosis upregulated cytokines and chemokine

164 Femoral deep vein thrombosis was diagnosed in 5 of 12 patients w

165 Cannula-associated deep vein thrombosis was found in 75 patients (71.4%) de

166 dies, the weighted frequency of PICC-related deep vein thrombosis was highest in patients who were cr

167 8%), a femoral associated cannula-associated deep vein thrombosis was identified in 10 patients (76.9

168 A jugular associated cannula-associated deep vein thrombosis was identified in seven patients (5

169 Deep vein thrombosis was induced in the inferior vena ca

170 Deep vein thrombosis was not associated with thromboprop

171 Deep vein thrombosis was present only in five of 41 (12.

172 screened high-risk patients, 20 asymptomatic deep vein thrombosis were detected with venous duplex ul

173 21 years, 52% women) with acute iliofemoral deep vein thrombosis were randomized to receive ultrasou

174 t of the study was the prevalence of femoral deep vein thrombosis within 48 h of SPCU admission, anal

175 for pulmonary embolism, 1% (29 of 2327) for deep vein thrombosis, 7% (61 of 866) for sepsis, 16% (22

176 Finally, complications (pulmonary embolism, deep vein thrombosis, acute respiratory distress syndrom

177 thrombus and plasma of baboons subjected to deep vein thrombosis, an example of inflammation-enhance

178 re hospitalized for proximal lower-extremity deep vein thrombosis, and 3649 patients (4.1%) underwent

179 failure, urinary tract infection, pneumonia, deep vein thrombosis, and myocardial infarction were ind

180 ons such as ventilator-associated pneumonia, deep vein thrombosis, and pressure sores; and shortened

181 ors for venous thromboembolism, proximal leg deep vein thrombosis, and pulmonary embolism developing

182 ons including myocardial infarction, stroke, deep vein thrombosis, and pulmonary embolism.

183 ere obtained for provoked/unprovoked events, deep vein thrombosis, and pulmonary embolism.

184 hree patients had femoral cannula-associated deep vein thrombosis, and two had an oxygenator or pump

185 s, any infection, hemorrhage, renal failure, deep vein thrombosis, and uncontrollable intracranial hy

186 no IVC filter vs IVC filter on PE, fatal PE, deep vein thrombosis, and/or mortality in trauma patient

187 mortality, ventilator-associated pneumonia, deep vein thrombosis, depression, and hostility.

188 ab group, and grade 2 thrombosis and grade 2 deep vein thrombosis, each in one patient in the chemoth

189 rtions of treated HIV-infected patients with deep vein thrombosis, hepatitis C, renal impairment, thy

190 The use of thrombolysis for occlusive deep vein thrombosis, in attempt to reduce the long-term

191 y disseminated intravascular coagulation and deep vein thrombosis, in tuberculosis (TB) patients.

192 ow-up, acute RV dysfunction, with or without deep vein thrombosis, is more common, but acute LV systo

193 For patients with acute iliofemoral deep vein thrombosis, it remains unclear whether the add

194 pulmonary embolism at 6 months, symptomatic deep vein thrombosis, major bleeding, death at 3 and 6 m

195 redictors of PE (obesity, pregnancy, cancer, deep vein thrombosis, major procedure, spinal cord paral

196 onary artery disease, obesity, hypertension, deep vein thrombosis, male sex, high-sensitivity C-react

197 , but also contribute to the pathogenesis of deep vein thrombosis, myocardial infarction and stroke.

198 mortality in the developed world, underlying deep vein thrombosis, myocardial infarction, and stroke.

199 efficacy end point was the composite of any deep vein thrombosis, nonfatal pulmonary embolism, or al

200 ts (catheter-related blood stream infection, deep vein thrombosis, occlusion, pain, infiltration, ble

201 n of statin use with venous thromboembolism, deep vein thrombosis, or pulmonary embolism in adults we

202 nd collected data on venous thromboembolism, deep vein thrombosis, or pulmonary embolism outcomes.

203 botic events (myocardial infarction, stroke, deep vein thrombosis, or pulmonary embolism) and haemorr

204 In patients with acute iliofemoral deep vein thrombosis, PCDT did not influence the occurre

205 edical complications (myocardial infarction, deep vein thrombosis, pulmonary embolism, and pneumonia)

206 ing (micro)thrombotic complications, such as deep vein thrombosis, pulmonary embolism, and stroke.

207 omatic venous thromboembolism was defined as deep vein thrombosis, pulmonary embolism, or both, diagn

208 s of acute renal failure requiring dialysis, deep vein thrombosis, pulmonary embolism, sepsis, pneumo

209 ents ranging from repeated thrombophlebitis, deep vein thrombosis, pulmonary embolism, transitory isc

210 fibrillation, supraventricular tachycardia, deep vein thrombosis, respiratory depression, atelectasi

211 re observed in rates of postoperative ileus, deep vein thrombosis, small bowel obstruction, urinary s

212 ents (76.9%) had isolated cannula-associated deep vein thrombosis, two patients (15.4%) had isolated

213 ransgenic reporter mice, we demonstrate that deep vein thrombosis-recruited TEM receive an immediate

214 patient had central venous catheter-related deep vein thrombosis.

215 embolism manifested as pulmonary embolism or deep vein thrombosis.

216 none or placebo stockings) in patients with deep vein thrombosis.

217 even patients (84.6%) had cannula-associated deep vein thrombosis.

218 al stay less than 2 days, or had preexisting deep vein thrombosis.

219 ng post thrombotic syndrome in patients with deep vein thrombosis.

220 es analysed were mortality and recurrence of deep vein thrombosis.

221 , or between extrapulmonary tuberculosis and deep vein thrombosis.

222 t thrombus organization in a murine model of deep vein thrombosis.

223 ation and PAD4 as potential drug targets for deep vein thrombosis.

224 as the source of the prothrombotic effect in deep vein thrombosis.

225 ment of such diseases as atherosclerosis and deep vein thrombosis.

226 and all of them developed cannula-associated deep vein thrombosis.

227 l thromboplastin time, prothrombin time, and deep vein thrombosis.

228 both femoral and jugular cannula-associated deep vein thrombosis.

229 tor for VTEs, such as pulmonary embolism and deep vein thrombosis.

230 sociated risk factors for cannula-associated deep vein thrombosis.

231 le scans, 92 (34%, 95% CI 28-40) had femoral deep vein thrombosis.

232 ndrome (PTS) in patients with acute proximal deep vein thrombosis.

233 omboembolic events, driven by a reduction in deep vein thrombosis.

234 17), and survival (p=0.45) were unrelated to deep vein thrombosis.

235 anced cancer admitted to SPCUs had a femoral deep vein thrombosis.

236 imb oedema (p=0.009) independently predicted deep vein thrombosis.

237 of PCDT in ATTRACT patients with iliofemoral deep vein thrombosis.

238 14.5% mortality, 43.7% disability, and 9.8% deep vein thrombosis.

239 rade 3 to 5 nonhematologic toxicity included deep vein thrombosis/pulmonary embolism (21%), hemorrhag

240 ively), whereas most venous studies examined deep vein thrombosis/pulmonary embolus prevention (42%)

241 clinical patients with platelet activation (deep vein thrombosis; saphenous vein graft occlusion aft

242 ially lower for pulmonary embolism (54%) and deep-vein thrombosis (44%) than heart attack (88%) and s

243 Deep-vein thrombosis (DVT) is regarded a chronic disease

244 FVL mutation poses a clearly higher risk for deep-vein thrombosis (DVT) than for pulmonary embolism.

245 hlegmasia/VLG) after initiating treatment of deep-vein thrombosis (DVT); in 8 patients, cancer was no

246 Eligible patients with deep-vein thrombosis (EINSTEIN-DVT) or pulmonary embolis

247 al [CI], 0.51-0.90; P=0.008), including both deep-vein thrombosis (HR, 0.66; 95% CI, 0.47-0.92; P=0.0

248 ostic techniques (compression ultrasound for deep-vein thrombosis and computed tomography pulmonary a

249 pulmonary embolism indication, patients with deep-vein thrombosis and concomitant pulmonary embolism

250 e comprise the major arterial thromboses and deep-vein thrombosis and pulmonary embolism comprise ven

251 or the treatment and secondary prevention of deep-vein thrombosis and pulmonary embolism has been sho

252 Because the clinical diagnosis of deep-vein thrombosis and pulmonary embolism is nonspecif

253 Superficial-vein thrombosis can lead to deep-vein thrombosis and pulmonary embolism.

254 ome was a composite of asymptomatic proximal deep-vein thrombosis and symptomatic venous thromboembol

255 lism), we randomly assigned patients without deep-vein thrombosis at screening to receive rivaroxaban

256 he treatment period or asymptomatic proximal deep-vein thrombosis at the end of treatment.

257 o difference in the primary end point of leg deep-vein thrombosis but a reduced rate of pulmonary emb

258 requently develops in patients with proximal deep-vein thrombosis despite treatment with anticoagulan

259 Risk factors for deep-vein thrombosis have been shown not to be always th

260 p-vein thrombosis in an upper limb or distal deep-vein thrombosis in a lower limb, and death from ven

261 composite of objectively confirmed proximal deep-vein thrombosis in a lower limb, pulmonary embolism

262 lower limb, pulmonary embolism, symptomatic deep-vein thrombosis in an upper limb or distal deep-vei

263 was symptomatic, radiographically confirmed, deep-vein thrombosis in the arm or leg or pulmonary embo

264 right-sided PICC were more likely to develop deep-vein thrombosis in the ipsilateral arm (HR 3.37, 95

265 were significantly more likely to develop a deep-vein thrombosis in the ipsilateral arm compared wit

266 ged at least 18 years with acute symptomatic deep-vein thrombosis or acute symptomatic pulmonary embo

267 oagulant drugs and SFJ ligation); subsequent deep-vein thrombosis or pulmonary embolism occurred in 9

268 had symptomatic or incidental acute proximal deep-vein thrombosis or pulmonary embolism to receive or

269 ated use of medical resources; no subsequent deep-vein thrombosis or pulmonary embolism was observed

270 cial-vein thrombosis in terms of symptomatic deep-vein thrombosis or pulmonary embolism, progression

271 icacy outcome was a composite of symptomatic deep-vein thrombosis or pulmonary embolism, progression

272 hylaxis would result in a lower incidence of deep-vein thrombosis than pharmacologic thromboprophylax

273 antly lower incidence of proximal lower-limb deep-vein thrombosis than pharmacologic thromboprophylax

274 ly assigned 692 patients with acute proximal deep-vein thrombosis to receive either anticoagulation a

275 During follow-up, popliteal deep-vein thrombosis was diagnosed in 1 patient (0.21%;

276 bolism (pulmonary embolism or any lower-limb deep-vein thrombosis) occurred in 103 of 991 patients (1

277 h comprised events of pulmonary embolism and deep-vein thrombosis) was more common in the PFO closure

278 ptomatic pulmonary embolism (with or without deep-vein thrombosis) were assigned to receive edoxaban

279 edications included warfarin (presumably for deep-vein thrombosis), antihypertensive agents, and a st

280 A total of 4921 patients presented with deep-vein thrombosis, and 3319 with a pulmonary embolism

281 ) with an objectively confirmed diagnosis of deep-vein thrombosis, and an indication to receive antic

282 Preoperative albumin, postoperative deep-vein thrombosis, and electrolyte levels were associ

283 ostate cancer, hypertension, hyperlipidemia, deep-vein thrombosis, and stroke.

284 outcome was the composite of any symptomatic deep-vein thrombosis, any nonfatal pulmonary embolism, a

285 was incident (i.e., new) proximal lower-limb deep-vein thrombosis, as detected on twice-weekly lower-

286 ein thrombosis, or asymptomatic proximal-leg deep-vein thrombosis, as detected with the use of system

287 e, non-interventional study of patients with deep-vein thrombosis, done in hospitals and community ca

288 from the YEARS algorithm (clinical signs of deep-vein thrombosis, hemoptysis, and pulmonary embolism

289 mboembolism, pulmonary embolism, symptomatic deep-vein thrombosis, or asymptomatic proximal-leg deep-

290 composite of symptomatic distal or proximal deep-vein thrombosis, pulmonary embolism, or venous thro

291 Among patients with acute proximal deep-vein thrombosis, the addition of pharmacomechanical

292 mptomatic pulmonary embolism with or without deep-vein thrombosis, we compared rivaroxaban (15 mg twi

293 d anticoagulant therapy for the treatment of deep-vein thrombosis, without the need for laboratory mo

294 and unprovoked VTE, pulmonary embolism, and deep-vein thrombosis.

295 elated bloodstream infection and symptomatic deep-vein thrombosis.

296 erythrodysesthesia, cerebral ischaemia, and deep-vein thrombosis.

297 n ultrasonography for women with symptoms of deep-vein thrombosis; if the results were positive (i.e.

298 of graduated compression stockings (GCS) for deep vein thrombus (DVT) prophylaxis in acute stroke pat

299 Furthermore, unresolved human deep vein thrombus specimens stained positively with ant

300 e-way movement of blood from superficial and deep veins towards the heart.